This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Oncology  • Breast Cancer  • Ovarian Cancer  • Patient Education/ Health Literacy  • Women's Health, Other  • Genetic Counseling/ Testing/ Therapy  • Alert me on articles by topic

JAMA. 2004;292:796-798.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MMWR. 2004;53:603-606

2 tables omitted

Breast and ovarian cancer are the second and fifth leading causes of cancer death, respectively, among women in the United States.¹ One in eight women will have breast cancer during their lifetimes, and one in 70 will have ovarian cancer. Mutations in two genes, BRCA1 and BRCA2 (BRCA1/2), are associated with predisposition for inherited breast and ovarian cancer and are identified in 5%-10% of women with breast or ovarian cancer (BOC).² Since 1996, genetic testing for these mutations has been available clinically³; however, population-based screening is not recommended because of the complexity of test interpretation and limited data on clinical validity and utility.^1,4-6 Despite the test's limited applicability in the general population, the U.S. provider of clinical BRCA1/2 testing (Myriad Genetic Laboratories, Inc., Salt Lake City, Utah) conducted a pilot direct-to-consumer (DTC) marketing campaign in two cities (Atlanta, Georgia, and Denver, Colorado) during September . . . [Full Text of this Article]